文献速递骨质疏松与代谢性骨病

绝经后骨质疏松患者从双膦酸盐转换为地舒单抗、特立帕肽或罗莫佐单抗的影响:病例对照研究

Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study.
PubMed 文献 · Osteoporos Int · 2025-01-16

这项回顾性、病例对照、多中心研究纳入389例因双膦酸盐疗效不佳而转换治疗的患者,经倾向评分匹配后每组45例。转换治疗12个月后,罗莫佐单抗组腰椎骨密度增幅11.4%,显著高于地舒单抗组6.3%和特立帕肽组5.9%(均p<0.001);罗莫佐单抗组全髋骨密度增幅3.3%,高于特立帕肽组0.8%(p<0.01);仅罗莫佐单抗组股骨颈骨密度较基线显著增加2.0%(p<0.01)。

要点

  • 罗莫佐单抗组腰椎骨密度增幅11.4%,显著高于地舒单抗组6.3%和特立帕肽组5.9%。
  • 罗莫佐单抗组全髋骨密度增幅3.3%,高于特立帕肽组0.8%。
  • 仅罗莫佐单抗组股骨颈骨密度较基线显著增加2.0%。

核心结论

  • 所有组腰椎骨密度均显著增加,罗莫佐单抗组和地舒单抗组全髋骨密度显著增加,仅罗莫佐单抗组股骨颈骨密度显著增加。
  • 罗莫佐单抗在双膦酸盐治疗后显示出最显著的骨密度改善。

研究设计与样本

  • 回顾性、病例对照、多中心研究,纳入389例因双膦酸盐疗效不佳而转换治疗的患者,经倾向评分匹配后每组45例。
  • 基线平均年龄73.8岁,既往双膦酸盐治疗时长37.1个月,腰椎骨密度T值-2.8,全髋-2.5,股骨颈-2.7。
  • 评估12个月内的骨密度和骨转换标志物。

主要发现

  • 罗莫佐单抗组显示骨吸收标志物降低和骨形成标志物升高的双重效应;特立帕肽组两种标志物升高最明显;地舒单抗组两种标志物均被抑制。
  • 12个月后,罗莫佐单抗组腰椎骨密度增幅11.4%,显著高于地舒单抗组6.3%(p<0.001)和特立帕肽组5.9%(p<0.001)。
  • 罗莫佐单抗组全髋骨密度增幅3.3%,高于特立帕肽组0.8%(p<0.01)。
  • 仅罗莫佐单抗组股骨颈骨密度较基线显著增加2.0%(p<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers. PURPOSE: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis. METHODS: This retrospective, case-controlled, multicenter study included 389 patients who switched from BP to DMAb, TPTD, or ROMO due to treatment inefficacy. Propensity score matching was used to align patient backgrounds, resulting in 45 patients per group. Baseline characteristics included a mean age of 73.8 years, prior BP treatment duration of 37.1 months, and bone mineral density (BMD) T-scores of -2.8 in the lumbar spine (LS), -2.5 in the total hip (TH), and -2.7 in femoral neck (FN). BMD and bone turnover markers were assessed over 12 months. RESULTS: Following the switch from BP, the ROMO group demonstrated a dual effect of decreased bone resorption and increased bone formation markers. The TPTD group exhibited the highest increases in both markers, while the DMAb group suppressed both. After 12 months, the ROMO group demonstrated significantly greater BMD increases in the LS (11.4%) compared to the DMAb (6.3%; p < 0.001) and TPTD (5.9%; p < 0.001) groups. Additionally, the ROMO group showed greater increases in the TH (3.3%) than TPTD group (0.8%; p < 0.01). Only the ROMO group showed a significant BMD increase in the FN (2.0%; p < 0.01 from baseline). CONCLUSION: Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Yukishima T, Ebina K, Etani Y, et al. Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study. Osteoporos Int. 2025. PMID: 39821342. doi:10.1007/s00198-025-07386-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。